Onset
Not established; same-day reports are anecdotal.
Protocol / Research Dosing Guide
Adamax Dosage Guide: Research Schedule, Reconstitution and Safety
An evidence-organized Adamax research guide separating source-reported community practices from what has actually been established in published research.
Last reviewed September 15, 202616 minute readResearch information only
Level 1 — No direct compound studiesNo published human trialsNot FDA approved
Adamax Quick Start
Adamax is marketed as an N-acetylated, adamantane-modified Semax analogue. No peer-reviewed human, animal, or laboratory study of Adamax itself was identified. Semax findings cannot be assigned to Adamax.
Why researchers care
Cognitive and neurobiology research claims
Class
Vendor-created Semax analogue
Route reported
Intranasal and subcutaneous formats are sold
Cycle length
8 weeks reported; not validated
Regulatory status
Not FDA approved
Loading supplier information
Adamax Dosing Protocol and Schedule
The supplied source describes a once-daily, eight-week community titration from 300 mcg to 1,000 mcg. It explicitly states that this pattern is not tested or approved.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Weeks 1–2 | 300 mcg once daily | Community reported |
| Weeks 3–4 | 500 mcg once daily | Community reported |
| Weeks 5–6 | 750 mcg once daily | Community reported |
| Weeks 7–8 | 1,000 mcg once daily | Community reported |
No Adamax study validates these amounts, the titration, the eight-week duration, or a rest period.
Adamax Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
Adamax Reconstitution Calculator
Vial-format concentration math
Concentration
2.5 mg/mL
Draw volume
0.12 mL
U-100 units
12
Mathematical draws
16
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take Adamax: Morning or Night?
Morning or evening?
Not established. Morning use appears in community descriptions, not controlled research.
Once daily or split?
The supplied source reports once-daily use. No study establishes frequency.
With food?
Not applicable to intranasal or vial formats and not established for any oral Adamax product.
Missed amount?
No validated procedure exists. Do not infer replacement or doubling instructions.
Adamax Route Comparison
| Format | What is reported | Evidence limit |
|---|---|---|
| Intranasal | Premixed products are marketed | Absorption and dose are not established |
| Subcutaneous vial | Community titration is reported | No published safety or pharmacokinetic study |
| Route conversion | No conversion available | Formats are not interchangeable |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
Adamax Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human half-life | Not established | No human PK study |
| Animal half-life | Not established | No Adamax animal PK study |
| Brain exposure | Not established | No distribution study |
| Frequency | Once daily is source reported | Not experimentally validated |
Adamax Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous | 300 mcg | Once daily | Community report | No |
| Subcutaneous | 500 mcg | Once daily | Community report | No |
| Subcutaneous | 750 mcg | Once daily | Community report | No |
| Subcutaneous | 1,000 mcg | Once daily | Community report | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
Adamax Reconstitution Guide
Concentration: 2.5 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 0.3 mg | 0.12 mL | 12 units |
| 0.6 mg | 0.24 mL | 24 units |
| 0.9 mg | 0.36 mL | 36 units |
- 1.Confirm the exact vial label and quantity.
- 2.Choose and record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use only the calculated concentration for arithmetic.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How Adamax Works
Adamax identity
Commercial descriptions call it an adamantane-modified Semax analogue.
Adamax Human Trials and FDA Status
Current status · verified September 15, 2026
Not FDA approved
- No published Adamax human trial was identified.
- No published Adamax animal study was identified.
- No published Adamax laboratory pharmacology study was identified.
- Adamax is not FDA approved and has no established medical use.
Who Should Avoid Adamax?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No safety data
Children or adolescents
No safety data
Known ingredient sensitivity
Identity and excipient uncertainty
Neurologic or psychiatric conditions
Effects and interactions are unknown
Concurrent medicines
No interaction studies
Long-term or repeated use
No safety data
Adamax Side Effects, Risks and Safety
HeadacheAnecdotal
Important limitation: No controlled incidence data.
Nasal or injection-site irritationAnecdotal
Important limitation: Route-specific safety is unknown.
Sleep disturbanceAnecdotal
Important limitation: Causality is not established.
Allergic responseUnknown
Important limitation: No characterized safety dataset.
Drug interactionsUnknown
Important limitation: No interaction studies.
Long-term effectsUnknown
Important limitation: No follow-up evidence.
Adamax Timeline and Monitoring
Peak effect
Not established.
Eight-week source schedule
A community structure, not a measured clinical timeline.
Monitoring
No validated Adamax monitoring schedule or stopping rule exists.
Adamax Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Focus or attention | Not established | Vendor/community claim | No Adamax study |
| Memory or learning | Not established | Extrapolated from Semax | Different molecule |
| Motivation or mental energy | Not established | Anecdotal | No controlled data |
| Neuroprotection | Not established | Related-compound theory | No direct evidence |
Adamax Storage and Handling
Unreconstituted vial
No Adamax-specific stability study was identified; follow the exact product label.
Prepared vial
No validated Adamax storage duration was identified.
Premixed nasal product
Follow the product-specific label; no universal condition is established.
Appearance
Cloudiness, discoloration, or particles do not establish safe usability.
Adamax Troubleshooting
Solution appears cloudy
Stop and seek qualified product guidance; appearance cannot confirm sterility.
Calculated units look wrong
Recheck vial quantity, diluent volume, target unit, and U-100 conversion.
Nasal and vial amounts conflict
No validated route conversion exists.
Unexpected symptoms occur
No Adamax safety protocol exists; seek licensed clinical review.
A scheduled amount is missed
No validated missed-amount procedure exists.
Adamax Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Adamax | Commercial Semax analogue | No direct studies | Not approved |
| Semax | ACTH(4–7) analogue | Published preclinical and limited clinical literature | Not FDA approved |
| N-acetyl Semax | Modified Semax form | Not interchangeable with Adamax | Not FDA approved |
Adamax Frequently Asked Questions
What is Adamax?
A commercially described adamantane-modified Semax analogue without direct published research.
Is Adamax FDA approved?
No.
Are there human trials?
No published Adamax human trial was identified.
What is its half-life?
Not established.
Is nasal absorption known?
No Adamax nasal absorption study was identified.
Is the community schedule validated?
No. It is source-reported anecdotal information.
Can Semax findings be used for Adamax?
No. Related-compound evidence cannot establish Adamax effects.
Is there a validated rest period?
No.
What does the calculator do?
It converts entered vial and liquid values into concentration and U-100 volume math only.
Is long-term safety known?
No.
Sources and Research
Coverage source
1. Adamax protocol coverage source
Community schedule and information categories; not primary evidence.
Open direct sourceRelated-compound research
2. Semax rapidly increases BDNF expression in rat hippocampus
Related-compound animal context only; does not test Adamax.
Open direct sourceRelated-compound research
3. Semax effects on BDNF/TrkB expression
Rat Semax study; cannot establish Adamax pharmacology.
Open direct sourceMissing information flagged for review
- Direct identity/pharmacology study: Not established
- Human or animal dosage: Not established
- Half-life: Not established
- Route bioavailability: Not established
- Validated cycle and rest period: Not established
- Compound-specific stability: Not established
- Long-term safety: Not established
- Drug interactions: Not established